Breaking News

AzurRx BioPharma Acquires First Wave Bio Inc.

Expands its GI development pipeline and positions itself for new growth opportunities in the inflammatory bowel disease therapeutic space.

Author Image

By: Charlie Sternberg

Associate Editor

AzurRx BioPharma Inc., a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, has entered a definitive agreement to acquire First Wave Bio, Inc. in a stock and cash transaction valued at $229 million, including certain development, regulatory and sales milestones.   First Wave Bio is a clinical-stage biotechnology company specializing in the development of novel, gut-targeted, small molecule therapies for auto-immune inflammatory bowel d...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters